Skip to main content
. Author manuscript; available in PMC: 2012 Dec 5.
Published in final edited form as: Cancer Res. 2011 Aug 25;71(20):6360–6370. doi: 10.1158/0008-5472.CAN-11-0362

Figure 4. Genes and gene expression pathways associated with NR3C1-high (versus NR3C1-low) tumors divided by ESR1 (ER) status.

Figure 4

The number of differentially expressed genes (either 1.5-fold induced or repressed) between the highest versus lowest NR3C1 expression quartiles in ESR1+ and ESR1− breast cancers is shown. GeneGo’s MetaCore gene enrichment pathway analysis was then used to identify highly significant biological pathways from these differentially expressed genes in (ESR1) ER+ and (ESR1) ER− tumors.